People compare Semax and DSIP because both are research neuropeptides that circulate in the same nootropic and recovery discussions. The comparison is worth doing mostly to separate them: they are the same class but aimed at different problems, with the same preclinical evidence ceiling and the same regulatory status. The table above is the row-by-row breakdown. Below is what each row means.
Semax vs DSIP: the short version
Both are research neuropeptides with preclinical evidence, no published human randomized controlled trial, no registered trial, and no approval in any major jurisdiction. Both are on the same FDA compounding agenda for July 24, 2026. The real difference is the target: Semax is studied around cognition and neuroprotection, DSIP around sleep. Putting them head-to-head as if one wins is comparing two different goals.
Evidence: both preclinical, neither in trials
What is known about either comes from cell and animal studies. Semax, an ACTH(4-7) analog, has been studied for neuroprotective and cognitive effects, including in cerebral-ischemia models. DSIP, the delta sleep-inducing peptide, has been studied for sleep regulation and stress responses. Neither has a registered human trial in the major registries, and neither has a published randomized controlled trial. For how we weigh these tiers, see our how we grade evidence explainer, the full Semax evidence and regulatory record, and the DSIP evidence and regulatory record.
Different targets, same class
Semax is a short peptide derived from ACTH, studied for effects on attention, neuroprotection and recovery after ischemic events. DSIP is a nonapeptide named for its association with delta-wave sleep, studied around sleep onset, stress and withdrawal. They are both neuropeptides, which is why they get discussed together, but they are aimed at different outcomes — one cognitive, one sedative. There is no sourced basis for “Semax beats DSIP” or the reverse, because they are not solving the same problem.
Regulation: the same July 2026 vote
Both were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee votes on both on July 24, 2026 — for Semax the evaluated indications are cerebral ischemia, migraine and trigeminal neuralgia; for DSIP they are opioid withdrawal, chronic insomnia and narcolepsy. We track the meeting in the July 2026 FDA peptide meeting, explained. Neither carries a marketing authorization in the European Union, and as non-approved substances both should be treated as prohibited under anti-doping rules.
So which one, if either?
There is no winner here, because the two are not competing. Both are unproven in humans and neither has a registered trial; the choice between them is really a choice between two different goals — cognition or sleep — each unsupported by human efficacy data in 2026. Watch the July 2026 vote for the next real change.
Research information only. Neither Semax nor DSIP is approved for human use. Talk to a licensed physician before considering any peptide.